No profile data available.
Psyence Biomedical Ltd. (PBM) is a healthcare company in the brain and nerve treatment drugs industry, based in Toronto, Canada, with about 12 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of $1.01 million. In Q2 2026 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $3.39 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of December 4, 2025.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.
Psyence Biomedical reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$3.39 million as of December 4, 2025.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Alzamend Neuro, Inc. (ALZN), Silo Pharma, Inc. (SILO), Jupiter Neurosciences, Inc. (JUNS), Oragenics, Inc. (OGEN).